Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On November 28, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Nomura in Tokyo, Japan, scheduled for December 4-5, 2025. This engagement underscores the company’s proactive approach in maintaining transparency and fostering relationships with institutional investors, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, based in Hyderabad, India. The company is known for its production of generic medicines, active pharmaceutical ingredients, and proprietary products, focusing on delivering affordable and innovative healthcare solutions globally.
Average Trading Volume: 1,032,881
Technical Sentiment Signal: Buy
Current Market Cap: $11.65B
Learn more about RDY stock on TipRanks’ Stock Analysis page.